Advertisement

#IDWeek 2018

The U.N. General Assembly Hall during the High-level Meeting on HIV/AIDS.

Conferences

Merck Files With FDA for Expanded Approval of Pifeltro and Delstrigo

An OK would add an indication for the use of these HIV medications among those switching from stable regimens.

Tivicay

Tivicay Plus Boosted Prezista Shows Promise as Two-Drug HIV Regimen

However, the regimen appears much less potent for those who aren’t virally suppressed.

Switching to Janssen’s Symtuza Is Safe and Effective Up to 96 Weeks

Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.

Researchers Report Rare PrEP Failure in San Francisco

Experts emphasize that Truvada for HIV prevention remains highly effective.

Switching to Merck’s New HIV Regimen Delstrigo Is Safe and Effective

According to 48-week data from a recent study, Delstrigo posted good marks against other HIV treatments.

Advertisement